Private Capital Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Private Capital Group’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$66K	Sell	233 -28	-11%	-$7.49K	0.05%	381
2022 Q1	$68K	Buy	261 +4	+2%	+$949	0.02%	537
2021 Q4	$56K	Sell	257 -16	-6%	-$3.11K	0.01%	635
2021 Q3	$50K	Sell	273 -12	-4%	-$2.34K	0.01%	677
2021 Q2	$58K	Buy	285 +20	+8%	+$4.18K	0.01%	616
2021 Q1	$57K	Sell	265 -253	-49%	-$55.6K	0.01%	587
2020 Q4	$122K	Buy	518 +17	+3%	+$3.9K	0.02%	438
2020 Q3	$136K	Sell	501 -284	-36%	-$78.4K	0.03%	366
2020 Q2	$228K	Buy	785 +151	+24%	+$40.9K	0.05%	255
2020 Q1	$151K	Buy	634 +18	+3%	+$4.13K	0.04%	307
2019 Q4	$134K	Buy	616 +93	+18%	+$18.8K	0.03%	365
2019 Q3	$89K	Buy	523 +255	+95%	+$45.1K	0.02%	522
2019 Q2	$46K	Buy	268 +16	+6%	+$2.8K	0.01%	706
2019 Q1	$46K	Sell	252 -1	-0.4%	-$185	0.01%	818
2018 Q4	$42K	Buy	253 +3	+1%	+$520	0.01%	754
2018 Q3	$48K	Sell	250 -18	-7%	-$3.21K	0.01%	741
2018 Q2	$45K	Sell	268 -18	-6%	-$2.79K	0.01%	745
2018 Q1	$47K	Sell	286 -3,094	-92%	-$505K	0.01%	716
2017 Q4	$12	Buy	+3,380	New	+$500K	﹤0.01%	1291

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Private Capital Group's VRTX Position: Q2 2022 in Review

Private Capital Group reduced its Vertex Pharmaceuticals (VRTX) stake by 11% in Q2 2022, selling an estimated $7.49K and leaving 233 shares worth $66K. The position accounts for 0.05% of the portfolio, ranked #381.

Private Capital Group first reported a position in VRTX in Q4 2017 and has held it in 19 quarters since. The position peaked at $228K in Q2 2020. 1,107 funds tracked by Wall St. Rank hold VRTX as of Q2 2022.

Private Capital Group held 233 shares of Vertex Pharmaceuticals worth $66K as of Q2 2022.
Private Capital Group sold 28 Vertex Pharmaceuticals shares in Q2 2022, an estimated $7.49K.
Vertex Pharmaceuticals made up 0.05% of Private Capital Group's portfolio in Q2 2022, its #381 holding.
Private Capital Group first reported a position in Vertex Pharmaceuticals in Q4 2017 and has held it in 19 quarters since.
Private Capital Group's Vertex Pharmaceuticals position peaked at $228K in Q2 2020.
1,107 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2022.

Based on Private Capital Group's 13F filing for Q2 2022, filed 28 Jul 2022.